NATIONAL BUREAU OF ECONOMIC RESEARCH
NATIONAL BUREAU OF ECONOMIC RESEARCH

When Is Prevention More Profitable than Cure? The Impact of Time-Varying Consumer Heterogeneity

Michael Kremer, Christopher M. Snyder

NBER Working Paper No. 18862
Issued in March 2013
NBER Program(s):   EFG   HC

We argue that in pharmaceutical markets, variation in the arrival time of consumer heterogeneity creates differences between a producer's ability to extract consumer surplus with preventives and treatments, potentially distorting R&D decisions. If consumers vary only in disease risk, revenue from treatments--sold after the disease is contracted, when disease risk is no longer a source of private information--always exceeds revenue from preventives. The revenue ratio can be arbitrarily high for sufficiently skewed distributions of disease risk. Under some circumstances, heterogeneity in harm from a disease, learned after a disease is contracted, can lead revenue from a treatment to exceed revenue from a preventative. Calibrations suggest that skewness in the U.S. distribution of HIV risk would lead firms to earn only half the revenue from a vaccine as from a drug. Empirical tests are consistent with the predictions of the model that vaccines are less likely to be developed for diseases with substantial disease-risk heterogeneity.

download in pdf format
   (378 K)

email paper

The NBER Bulletin on Aging and Health provides summaries of publications like this.  You can sign up to receive the NBER Bulletin on Aging and Health by email.

Machine-readable bibliographic record - MARC, RIS, BibTeX

Document Object Identifier (DOI): 10.3386/w18862

Published: Preventives Versus Treatments* Michael Kremer and Christopher M. Snyder The Quarterly Journal of Economics (2015) 130 (3): 1167-1239. doi: 10.1093/qje/qjv012

Users who downloaded this paper also downloaded these:
McCullough, Parente, and Town w18684 Health Information Technology and Patient Outcomes: The Role of Organizational and Informational Complementarities
Cafiero w18861 What do we Really Know about Food Security?
Hoxby and Avery w18586 The Missing "One-Offs": The Hidden Supply of High-Achieving, Low Income Students
Danzon, Mulcahy, and Towse w17174 Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition and Procurement
Lichtenberg w18235 Pharmaceutical Innovation and Longevity Growth in 30 Developing and High-income Countries, 2000-2009
 
Publications
Activities
Meetings
NBER Videos
Themes
Data
People
About

National Bureau of Economic Research, 1050 Massachusetts Ave., Cambridge, MA 02138; 617-868-3900; email: info@nber.org

Contact Us